StreetInsider.com News Articles

Form 6-K Lakefront Biotherapeutic For: Oct 20

Tue, 20 Oct 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20261020/27210951.html

Morgan Stanley Assumes Lakefront Biotherapeutics (LKFT) at Equalweight

Tue, 20 Oct 2026 03:09:06 -0400

(Updated - October 20, 2026 3:09 AM EDT)

Morgan Stanley analyst Chris Yu assumes coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Equalweight rating and a price target of $26.00.

The analyst comments: “We are Equal-weight on LKFT with a $26 PT, as gamgertamig (BCMAxCD3) contributes modestly to our model due to the limited economics retained by LKFT, and we note potential business development is a key variable. We see a potential blockbuster opportunity for a safer BCMA T cell engager like gamgertamig in autoimmune indications. However, clinical data for gamgertamig is relatively limited, and LKFT's broader collaboration with GILD may limit

Morgan Stanley Assumes Lakefront Biotherapeutics (LKFT) at Equalweight

Tue, 20 Oct 2026 03:09:06 -0400

(Updated - October 20, 2026 3:09 AM EDT)

Morgan Stanley analyst Chris Yu assumes coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Equalweight rating and a price target of $26.00.

Form 6-K Lakefront Biotherapeutic For: Oct 14

Thu, 15 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261015/27188964.html

Lakefront sells cell therapy pipeline for €8M upfront plus milestones

Wed, 14 Oct 2026 16:02:35 -0400

Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company, according to a press release.

The deal includes an upfront payment of €8 million, potential milestone payments of up to $230 million, and a low-single-digit royalty to Lakefront.

The assets sold include preclinical multi-targeting and armed CAR-T constructs originally developed by AboundBio, which Lakefront — previously known as Galapagos NV — acquired in 2022. The constructs are designed to improve the potency and persistence of CAR-T therapies and address treatment resistance in hematological and solid tumors.

Armed

Lakefront sells cell therapy pipeline for €8M upfront plus milestones

Wed, 14 Oct 2026 16:02:35 -0400

The deal includes an upfront payment of €8 million, potential milestone payments of up to $230 million, and a low-single-digit royalty to Lakefront.

Armed

Form 6-K Lakefront Biotherapeutic For: Oct 13

Tue, 13 Oct 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20261013/27181619.html

Form 6-K Lakefront Biotherapeutic For: Oct 08

Fri, 09 Oct 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20261009/27172384.html

Form 6-K Lakefront Biotherapeutic For: Oct 06

Tue, 06 Oct 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20261006/27156193.html

Form 6-K Lakefront Biotherapeutic For: Sep 29

Tue, 29 Sep 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260929/27123048.html

Form 6-K Lakefront Biotherapeutic For: Sep 22

Wed, 23 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260923/27092827.html

RBC Capital Upgrades Lakefront Biotherapeutics (LKFT) to Outperform

Wed, 23 Sep 2026 03:53:54 -0400

RBC Capital analyst Brian Abrahams upgraded Lakefront Biotherapeutics (NASDAQ: LKFT) from Sector Perform to Outperform with a price target of $45.00 (from $26.00).

The analyst comments: “We are upgrading LKFT to Outperform from Sector Perform, adding Spec risk based on clinical/regulatory uncertainties potentially impacting revenue, and increasing our tgt to $45 from $26. We believe there is meaningful opportunity for gamgertamig in rare autoimmune diseases (peak non-prob.-adjusted royalties est. up to $885M) based on its potential efficacy across several indications and differentiated safety profile, near-term data should further de-risk the program and potentially draw greater investor interest, recent CAR-T hiccups may

RBC Capital Upgrades Lakefront Biotherapeutics (LKFT) to Outperform

Wed, 23 Sep 2026 03:53:54 -0400

RBC Capital analyst Brian Abrahams upgraded Lakefront Biotherapeutics (NASDAQ: LKFT) from Sector Perform to Outperform with a price target of $45.00 (from $26.00).

Form 6-K Lakefront Biotherapeutic For: Sep 15

Tue, 15 Sep 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260915/27065214.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26975179.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26975179.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26975179.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26972580.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26972580.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26972580.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260825/26972562.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260825/26972562.html

Form 6-K Lakefront Biotherapeutic For: Aug 25

Tue, 25 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260825/26972562.html

TD Cowen Starts Lakefront Biotherapeutics (LKFT) at Buy

Fri, 21 Aug 2026 05:12:05 -0400

TD Cowen analyst Phil Nadeau initiates coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Buy rating.

The analyst comments "We are reinstating our Buy rating on LKFT following the completion of Gilead and Lakefront's acquisition of Ouro Medicines. With Lakefront trading at a negative enterprise value, we think the stock is positioned to create shareholder value should BCMAxCD3 TCE gamgertamig be successfully developed, and/or should management execute on additional promising business development opportunities."

For an analyst ratings summary and ratings history on Lakefront Biotherapeutics click here. For more ratings news on Lakefront Biotherapeutics click here.

Shares of Lakefront Biotherapeutics closed at

TD Cowen Starts Lakefront Biotherapeutics (LKFT) at Buy

Fri, 21 Aug 2026 05:12:05 -0400

TD Cowen analyst Phil Nadeau initiates coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Buy rating.

For an analyst ratings summary and ratings history on Lakefront Biotherapeutics click here. For more ratings news on Lakefront Biotherapeutics click here.

Shares of Lakefront Biotherapeutics closed at